Compare Abeona Therapeutics Inc (ABEO) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Stitch Fix Inc — how do they compare? Abeona Therapeutics Inc trades at $6.72 (market cap $373.32M), while Stitch Fix Inc trades at $3.56 (market cap $495.68M). The key difference: Stitch Fix Inc is the larger of the two by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SFIX | |
|---|---|---|
Market Cap | $373.32M | $495.68M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $5.83 |
52-Week Low | $4.17 | $3.06 |
Enterprise Value | $228.22M | $383.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Stitch Fix (SFIX) trades at $3.72, down 3.12% on the day, as the company continues its turnaround efforts with improving financial metrics. The stock shows bearish technical signals but fundamental progress with narrowing losses, a 43.66% gross margin, and three consecutive quarterly earnings beats. Recent news highlights AI-driven personalization initiatives and growing client spending, though the company remains unprofitable with negative cash flow.
The outlook suggests cautious optimism as SFIX stabilizes revenue near $1.3B and reduces net losses. Investment opportunity lies in the discounted valuation (P/S 0.39) and AI growth potential, but risks include persistent unprofitability, competitive pressure, and execution challenges in achieving sustained positive cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
